Avid Bioservices to Present At Biologics Manufacturing Conference.Business Editors & Health/Medical Writers BIOWIRE2K TUSTIN, Calif.--(BW HealthWire)--June 24, 2002 Avid Bioservices Inc. (Avid), a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM PPHM Peregrine Pharmaceuticals, Inc (stock symbol) pphm Parts Per Hundred Million ), today announced that Dr. William Jay Treat will speak at the Williamsburg BioProcessing Foundation's Raw Materials and Contract Services for Mammalian Cell Products Conference in Salt Lake City, June 23 through 25. Treat is Avid's head of business development and has expertise in the manufacture of biologics, such as purified proteins and monoclonal antibodies, which are used as therapeutics and diagnostic tools by biopharmaceutical companies. The presentation will address issues biological contract manufacturers face in order to support current Good Manufacturing Practices (cGMP) and federal Food and Drug Administration regulations while servicing multiple clients with varied needs. Treat will focus on the impact of one critical raw material -- powder cell culture media -- and how varied powder manufacturing processes result in unique service and manufacturing challenges for contract organizations. The presentation will include an overview of the current powder media manufacturing processes and details on how manufacturers can meet their clients' specific quality and regulatory requirements. With 15 years of biopharmaceutical industry experience, Treat facilitates new business contracts for Avid, which manufactures antibodies and proteins in stirred tank bioreactors using mammalian cell systems. In addition to his sales experience, he has expertise in the manufacture of biologics; development of liquid and powder media, buffers and flexible packaging systems; sterilization sterilization Any surgical procedure intended to end fertility permanently (see contraception). Such operations remove or interrupt the anatomical pathways through which the cells involved in fertilization travel (see reproductive system). , design control and Water for Injection systems; and bioprocess bi·o·proc·ess n. 1. A technique that produces a biological material, such as a genetically engineered microbial strain, for commercial use. 2. development and scale-up improvements. About Avid Bioservices Inc. Avid Bioservices provides a full range of cGMP contract manufacturing services for the biotechnology and biopharmaceutical industries. The company's comprehensive package of services includes highly specialized cell culture, process and analytical development work, in addition to full-scale manufacturing, purification, bulk packaging and regulatory support. For more information about Avid, visit www.avidbio.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual events or results may differ from the company's expectations as a result of risk factors discussed in Peregrine's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the company's report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended April 30, 2001 and on Form 10-Q Form 10-Q See 10-Q. for the quarter ended Jan. 31, 2002. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion